SpringWorks Therapeutics (SWTX) Aandeel Koers
SpringWorks Therapeutics Koers
De omzet is de afgelopen 24 jaar met 3,4% per jaar gegroeid tot 191,59 Miljoen USD. De winst per aandeel is de afgelopen 9 jaar met 9,1% per jaar gegroeid. De nettowinstmarge van SpringWorks Therapeutics ligt op -134,7% en is ten opzichte van -126,4% enkele jaren eerder gedaald. Analisten hanteren een mediaan koersdoel van 47,94 USD — dat impliceert 2,0% boven de huidige koers. Van de 11 analisten geven 0 het aandeel een koopadvies — per saldo een Houden-consensus.
SpringWorks Therapeutics aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
SpringWorks Therapeutics bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over SpringWorks Therapeutics
The business model of SpringWorks Therapeutics Inc. is focused on developing and commercializing innovative targeted therapies for patients with severe rare diseases and cancer. The company aims to identify promising drug candidates and advance them through clinical development to address unmet medical needs. SpringWorks Therapeutics Inc. collaborates with both academic institutions and industry partners to leverage its expertise and optimize the development of potential treatments. By utilizing targeted therapies, the company aims to provide effective and personalized solutions for patients, with a focus on improving their overall quality of life.
SpringWorks Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of SpringWorks Therapeutics Inc in the market include companies like Novartis, Pfizer, and Roche.
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing life-changing therapies for patients with severe rare diseases and cancer. Founded in 2017, SpringWorks Therapeutics is committed to delivering innovative treatments by leveraging its strategic collaborations and advanced drug development expertise. With a diverse pipeline of investigational therapies, the company aims to address unmet medical needs and improve patients' lives globally. SpringWorks Therapeutics Inc has made significant progress in its mission to transform the lives of patients through its dedication to scientific excellence and groundbreaking research in the field of precision medicine.
Some significant milestones achieved by SpringWorks Therapeutics Inc include the approval of their lead product candidate, Nirogacestat, for the treatment of desmoid tumors by the U.S. FDA. The company also received Fast Track and Orphan Drug designations for Nirogacestat, which further highlights its potential in addressing unmet medical needs. Additionally, SpringWorks Therapeutics Inc has successfully initiated multiple clinical trials evaluating various therapies for rare cancers and genetic diseases. These accomplishments demonstrate the company's commitment towards advancing innovative treatments and improving patients' lives.
SpringWorks Therapeutics Inc is primarily present in the United States.
SpringWorks Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for patients with severe rare diseases and cancer. The company's core values include dedication, integrity, and collaboration in their pursuit of discovering novel treatments. With a patient-centric approach, SpringWorks Therapeutics aims to improve the lives of individuals affected by these debilitating conditions. They prioritize scientific excellence and ethical practices to deliver safe and effective therapies. Through strategic partnerships and pioneering research, the company strives to bring hope and transformative solutions to patients in need. SpringWorks Therapeutics Inc is committed to making a lasting impact in the lives of patients and their families.
Analisten hanteren momenteel een gemiddeld koersdoel van 53,33 USD voor het aandeel SpringWorks Therapeutics (mediaan: 47,94 USD), oftewel +13,5 % ten opzichte van de laatste koers. De consensus is gebaseerd op 11 analistenratings.
11 analisten beoordelen het aandeel SpringWorks Therapeutics momenteel: 0 adviseren kopen, 8 houden en 3 verkopen. Voor 2026 verwachten analisten dat SpringWorks Therapeutics een omzet van 612,33 Miljoen USD en winst per aandeel van -0,84 USD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel SpringWorks Therapeutics op 41,89 EUR (46,99 USD).
Het aandeel SpringWorks Therapeutics (SWTX) is genoteerd aan 1 beurzen, waaronder: NASDAQ (SWTX).
SpringWorks Therapeutics is a biopharmaceutical company focused on developing therapeutics for patients with rare severe diseases. The business model involves developing innovative therapies with high medical necessity and making them accessible to the market. The company specializes in three main areas: oncology, inherited metabolic disorders, and neurological disorders. SpringWorks aims to develop new and effective therapies for each of these diseases. In the oncology sector, SpringWorks utilizes its expertise in drug discovery and development to create innovative cancer therapies. One of the leading products is Nirogacestat, a Notch pathway inhibitor that has the potential to be used against solid tumors that do not respond to other forms of therapy. In the inherited metabolic disorders division, SpringWorks is working on developing therapies for patients with rare diseases such as Niemann-Pick Type C syndrome. The company has partnered with Cydan Development, a company specializing in developing drugs for rare genetic disorders, for this purpose. In the field of neurological disorders, SpringWorks aims to develop therapies for patients with rare genetic diseases such as epilepsy and Huntington's disease. The company has initiated a collaboration with the Hospital for Sick Children in Toronto for this purpose. The company also has an innovative technology called "Biomarker Relocation" which allows for the identification of patients with certain rare diseases that are otherwise difficult to diagnose and treat. The technology is currently a significant component of SpringWorks' research and development efforts. In recent years, the company has raised capital through investments and collaborations for its business model. The funding has been based on venture capital from leading companies including Novartis Venture Fund, Pfizer Ventures, and OrbiMed. SpringWorks' business strategy also includes partnerships with other companies and research institutions. One collaboration, for example, exists with the Memorial Sloan Kettering Cancer Center, a leading institution in cancer research. The vision of SpringWorks is to play a leading role in the development of therapeutics for patients with rare diseases and to meet the medical need in this area. The company strives to improve the lives of patients with rare diseases and provide them with an optimal medication that alleviates their condition and enhances their quality of life. Overall, SpringWorks is an emerging player in the biotech industry, developing innovative therapeutics to address the needs of patients with rare diseases. With a presence in multiple medical specialties and a strong financing base, the company is poised to secure a position at the forefront of the biotech industry.
De verwachte omzet van SpringWorks Therapeutics bedraagt 612,33 Miljoen USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van SpringWorks Therapeutics bedraagt -62,17 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van SpringWorks Therapeutics bedraagt momenteel -56,03. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het SpringWorks Therapeutics-aandeel in te schatten.
De koers-omzetverhouding (P/S) van SpringWorks Therapeutics bedraagt momenteel 5,69. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het SpringWorks Therapeutics-aandeel.
De Eulerpool Kwaliteitsscore voor SpringWorks Therapeutics is 3/10.
De ISIN van SpringWorks Therapeutics is US85205L1070. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van SpringWorks Therapeutics is A2PRLN. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van SpringWorks Therapeutics is SWTX. Onder dit beurstickersymbool wordt het SpringWorks Therapeutics-aandeel op de beurs verhandeld.
SpringWorks Therapeutics aandeel
SpringWorks Therapeutics Peer Group
SpringWorks Therapeutics Ticker
SpringWorks Therapeutics FIGI
Alle fundamentals en diepgaande analyse van SpringWorks Therapeutics
Onze aandelenanalyse van het SpringWorks Therapeutics-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van SpringWorks Therapeutics. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: